(Q22306312)

2

object named as

Alexandra L. Quittner

0 references

A. Bruce Montgomery

6

object named as

A Bruce Montgomery

0 references

author name string

Karen S. McCoy

1

0 references

Christopher M. Oermann

3

0 references

Ronald L. Gibson

4

0 references

George Z. Retsch-Bogart

5

0 references

A. Bruce Montgomery

6

0 references

Karen S McCoy

1

0 references

Christopher M Oermann

3

0 references

Ronald L Gibson

4

0 references

George Z Retsch-Bogart

American Journal of Respiratory and Critical Care Medicine

5

0 references

language of work or name

English

0 references

publication date

November 2008

0 references

1 November 2008

0 references

published in

0 references

volume

178

0 references

issue

9

0 references

page(s)

921-928

0 references

921-8

0 references

cites work

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Patient-reported outcomes in cystic fibrosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Clinical trials in cystic fibrosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Defining a pulmonary exacerbation in cystic fibrosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Making sense of quality-of-life data.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Changes in the normal maximal expiratory flow-volume curve with growth and aging

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Measurement of health status. Ascertaining the minimal clinically important difference

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Microbiology of sputum from patients at cystic fibrosis centers in the United States

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride)

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577727

Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.

30 May 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1804OC

Administration of aerosolized antibiotics in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1804OC

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1804OC

Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1804OC

Validation of a Disease-Specific Measure of Health-Related Quality of Life for Children with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1804OC

Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1804OC

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1804OC

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1804OC

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1804OC

Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

21 January 2018

1 reference

12 December 2020

Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis

1 reference

12 December 2020

Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis

1 reference

12 December 2020

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

12 December 2020